ImmunoGen strives to reclaim for itself some of the success of its first drug, Kadcyla

After waiting three decades since its founding to see ImmunoGen’s first drug approval last year, CEO Dan Junius says investors sometimes ask why the company can’t just repeat that success with another drug...